Brief: Medivir's Treatments Show Tumor Control In HCC, Patients Handle Two Cycles

Medivir AB

05/10/2023 12:20

Oct 5 (Reuters) - Medivir AB  MEDIVIR.ST :
    * FOSTROX + LENVIMA CONTINUES TO SHOW PROMISING TUMOR
CONTROL IN
HCC, ALL PATIENTS HAVE NOW DOSED AT LEAST TWO TREATMENT CYCLES
    * COMBINATION REMAINS TOLERABLE WITH NO UNEXPECTED NEW
SAFETY
EVENTS AND ADVERSE EVENTS ARE TRANSIENT AND MANAGEABLE

Source text for Eikon:  ID:nWkr4llC5H 
Further company coverage:  MEDIVIR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))